Emyria (EMD) investor relations material

Executive summary

• Achieved FY 2026 revenue of AUD 4.3 million, a 210% increase year-over-year, driven by clinic expansion and insurer-funded patient demand.

• Activated new clinics in Victoria and Brisbane, advanced NSW expansion, and expanded the clinical workforce with over 100 trained clinicians.

• Perth Clinic, the most mature site, has reached profitability and demonstrated increasing utilization and operating leverage.

• Launched the Empax Global Partnership Program to diversify revenue and attract global partners, creating a high-margin, sponsor-funded revenue stream.

• Regulatory changes broadened eligible clinicians for psychedelic-assisted psychotherapy, supporting workforce growth.

Financial highlights

• Quarterly revenue reached AUD 1.53 million, including R&D income; FY26 revenue up 210% year-over-year.

• Cash position at quarter-end was AUD 7.29 million, with a quarterly cash burn of AUD 1.43 million, funding secured for over five quarters.

• Cash receipts for the quarter were AUD 1.05 million; net operating cash outflows mainly due to workforce and supply expansion.

• Each dosing day generates AUD 10,000 in revenue; full PTSD treatment yields AUD 33,000, and treatment-resistant depression AUD 22,000 per patient.

• Payments to related parties totaled AUD 158,000 for the quarter (Director fees and remuneration).

Outlook and guidance

• Sydney clinic opening targeted for late in the current quarter or Q3 CY2026, with plans to expand to all major capital cities and four jurisdictions.

• Pipeline for existing clinics is strong, with Perth booked well into the year and growing interest in Brisbane, Mornington, and Sydney.

• Expects continued growth in clinic utilization and profitability as new clinics mature.

• Anticipates improved cash receipt timeframes as third-party payment workflows optimize.

• Future drivers include new site announcements, additional funders, leveraging IP for global partnerships, and further regulatory approvals for expanded indications.